Е-Публикации
Технически университет - София

Abstract: Bisphosphonates are a group of drugs that are widely used in the treatment of osteoclast-mediated diseases related to bone loss. Since 2003 the problem of bisphosphonate-associated osteonecrosis of the jaws (BAONJ) has been raised, and many authors have published the cases they have observed. BAONJ is a multifactorial disease, and the risk factors for the development of the disease can be divided into those related to bisphosphonate therapy, local risk factors, demographic and systemic factors, genetic factors and preventive factors. The aim of the present study is to determine the effect of the duration of bisphosphonate intake on the outcome of bisphosphonate-associated osteonecrosis of the jaws (BAONJ) treatment using the statistical method one-dimensional logistic regression which is from the direction of regression analysis. In the present study we included 44 patients diagnosed with Bisphosphonate-associated osteonecrosis of the jaw (BAONJ). For each patient included in the study, information on the anamnesis, general and local status and results of clinical and paraclinical studies is recorded in an individual card. Our study shows that with the increase of the duration of BF intake, the likelihood of disease progression also increases, found in the examination of the patient on the first and on the sixth month after the treatment of BAONJ. Therefore, we can conclude that the factor duration of BF intake can be used as a predictor of the outcome of BAONJ treatment, and with increasing of its value, the likelihood of disease progression increases. Furthermore, we can suggest that the duration of bisphosphonate intake is an important factor that can lead to unfavourable clinical results in outpatient treatment of BAONJ.

References

1. Office of the Surgeon General (US) (2004) Bone Health and Osteoporosis: A Report of the Surgeon General, Rockville (MD), Office of the Surgeon General (US). Message from Tommy G. Thompson (available from: https://www.ncbi.nlm.nih.gov/books/NBK45522/).
2. Carey J. J. (2005) What is a ‘failure’ of bisphosphonate therapy for osteoporosis?, Cleve. Clin. J. Med., 72(11), 1033–1039.
3. Tiegs R. (1997) Paget’s disease of bone: indications for treatment and goals of therapy, Clin. Ther., 19(6), 1309–1329.
4. Berenson J., B. Hillner, R. Kyle et al. (2002) American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma, J. Clin. Oncol., 20(17), https://ascopubs.org/doi/10.1200/JCO.2002.06.037.
5. Badros A., D. Weikel, A. Salama et al. (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors, J. Clin. Oncol., 24(6), 945–952.
6. Bamias A., E. Kastritis, C. Bamia et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors, J. Clin. Oncol., 23(34), 8580–8587.
7. Ruggiero S. L., T. B. Dodson, J. Fantasia et al. (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update, J. Oral Maxillofac. Surg., 72, 1938–1956.
8. Hillner B., J. Ingle, R. Chlebowski et al. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer, JCO, 21(21), 4042–4057.
9. Body J. J. (2006) Breast cancer: bisphosphonate therapy for metastatic bone disease, Clin. Cancer Res., 12(20 Pt 2), 6258–6263.
10. Landesberg R., S. Eisig, I. Fennoy, E. Siris (2009) Alternative indications for bisphosphonate therapy, J. Oral Maxillofac. Surg., 67(5 Suppl), 27–34.
11. Devogelaer J. P. (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis, Curr. Opin. Rheumatol., 12(4), 331–335.
12. Bohach S., K. Gibson, M. Warman et al. (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta, Pediatrics, 111(3), 573–578.
13. Marx R. E. (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J. Oral Maxillofac. Surg., 61(9), 1115–1117.
14. Ruggiero S. L., T. B. Dodson, L. A. Assael et al. (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update, J. Oral Maxillofac. Surg., 67(5 Suppl), 2–12.
15. Hoff A. O., B. B. Toth, K. Altundag et al. (2006) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy, J. Clin. Oncol., 24(18), 8528.
16. Ruggiero S. L., B. Mehrotra, T. J. Rosenberg, S. L. Engroff (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases, J. Oral Maxillofac. Surg., 62(5), 527–534.
17. American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations, J. Am. Dent. Assoc., 137(8), 1144–1150.
18. StatSoft, Inc. (2011) STATISTICA Manual (Data analysis software system), Version 11.0.
19. Jobson J. D. (1991) Multivariate Data Analysis, vol.1,2, Springer Ver.
20. Choi N. R., J. H. Lee, J. Y. Park, D. S. Hwang (2020) Surgical treatment of medication-related osteonecrosis of the jaw: a retrospective study, Int. J. Environ. Res. Public Health, 17(23), 8801.

Issue

Full text of the publication